Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

← catalyst calendar

NCT04198766 · readout ≤ 2,538 d

Sponsored by Inhibrx Biosciences, Inc (industry) · INBX — their whole pipeline →. With Merck Sharp & Dohme LLC.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · Single · Treatment

Enrollment

340estimated

Sites

Countries

Singapore, South Korea, Taiwan +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2019-12-10

actual

When the study began enrolling

Primary completion

Jul 2033

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jul 2033

estimated

The whole study's end, after follow-up

First posted

2019-12-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Solid Tumor
Non-Small Cell Lung Cancer
Head and Neck Cancer
Melanoma
Gastric Cancer
Renal Cell Carcinoma
Urothelial Carcinoma
Resectable Non-Small-Cell Lung Cancer

Interventions

Drug: INBRX-106 - Hexavalent OX40 agonist antibody
Drug: pembrolizumab 200 mg — also filed as KEYTRUDA
Drug: pembrolizumab 400 mg — also filed as KEYTRUDA
Drug: Carboplatin AUC-5
Drug: Carboplatin AUC-6
Drug: Pemetrexed 500 mg/m2 — also filed as Alimta®
Drug: Cisplatin 75mg/m2
Drug: Paclitaxel 200mg/m2
Drug: Nab paclitaxel 100mg/m2
Drug: Gemcitabine (1000 mg/m2)

Primary outcomes

what the primary-completion date above is the date OF

Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab

measured ~2 years

Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab

measured ~2 years

MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab

measured ~2 years

Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts

measured ~2 years

Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC

measured ~2 years

To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)

measured ~2 years

Publications

PMID 40404202 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · INBX's whole pipeline · Catalyst calendar · Every registered study · What changed